IMAX added to key Russell indices

IMAX (IMAX) is drawing fresh attention after being added to both the Russell 2000 Defensive Index and the Russell 2000 Growth-Defensive Index, a shift that could influence index-tracking fund flows.

IMAX shares trade at $40.40 after a 1 day share price gain of 1.35%, while the 7 day share price return is down 8.01%. However, the 1 year total shareholder return of 48.86% and 3 year total shareholder return of about 2.4x suggest that longer term momentum has been strong.

If this index inclusion has you thinking about where else capital is moving, it could be a good moment to scan for other opportunities across 20 top founder-led companies

With IMAX trading at $40.40, an implied 23.5% discount to one intrinsic value estimate, investors are left with a key question: is this still a mispriced growth story, or is the market already banking on future gains?

Most Popular Narrative: 13.7% Undervalued

Compared with IMAX's last close at $40.40, the most followed narrative pegs fair value at $46.82, implying a discount that hinges on growth, margins, and cash generation assumptions.

Diversification of content offerings, including local-language blockbusters, alternative content (concerts, live events), and deeper relationships with streaming and tech partners like Apple, Amazon, and Netflix, is broadening IMAX's audience base and improving margin mix, contributing to higher contribution per screen and more resilient earnings.

Curious what justifies paying more than today’s price for IMAX? The narrative leans heavily on faster earnings, richer margins, and a very specific profit multiple. The key assumptions are bold, tightly linked, and far from universally agreed. The full story is in how those moving parts fit together.

Result: Fair Value of $46.82 (UNDERVALUED)

However, the IMAX narrative also leans on a healthy slate of blockbuster releases and capital intensive screen expansion, so any hit to film output or installation economics could quickly test these assumptions.

Another view on IMAX valuation

The narrative and DCF style fair value estimates suggest IMAX is undervalued, but the market price tells a different story when viewed through simple earnings multiples. IMAX trades on a P/E of 60.4x, compared with an estimated fair ratio of 25.9x and a US Entertainment industry average of 22.1x.

That gap means investors today are paying a much higher price for each dollar of current earnings, even though one internal model suggests the stock trades 23.5% below fair value. The key consideration is whether this is viewed as justified by potential changes in earnings or as valuation risk if expectations change.

Next Steps

With mixed signals around IMAX's valuation and outlook, the key question is how you interpret the balance of concern and optimism. Take a moment to review the details for yourself, then weigh up 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond IMAX?

If IMAX has sharpened your focus on valuation and narrative, do not stop here. Broader opportunity often sits in stocks the crowd has barely started watching.

• Target resilient performers with lower volatility by scanning 73 resilient stocks with low risk scores that may better match your comfort with downside risk.
• Hunt for companies trading below estimated worth by using the 41 high quality undervalued stocks to spot situations where expectations and prices look out of sync.
• Zero in on potential future standouts with the screener containing 19 high quality undiscovered gems before they attract wider attention and pricing becomes less forgiving.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.